

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:761US

Serial No.

10/629,329

List of Patents and Publications for Applicant's

Applicant

Bryant G. Darnay

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

July 29, 2003

Group:

Unknown

1646

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
RLi	C1	Bucay <i>et al.</i> , "Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification," <i>Genes Dev.</i> , 12:1260-1268, 1998.
	C2	Darnay <i>et al.</i> , "Activation of NF- κ B by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF- κ B-inducing kinase," <i>J. Biol. Chem.</i> , 274(12):7724-7731, 1999.
	C3	Darnay <i>et al.</i> , "Characterization of the intracellular domain of receptor activator of NF- κ B (RANK)," <i>J. Biol. Chem.</i> , 273(32):20551-20555, 1998.
	C4	Dougall <i>et al.</i> , "RANK is essential for osteoclast and lymph node development," <i>Genes Dev.</i> , 13:2412-2424, 1999.
	C5	Fujikawa <i>et al.</i> , "The human osteoclast precursor circulates in the monocyte fraction," <i>Endocrinol.</i> , 137(9):4058-4060, 1996.
	C6	GenBank Accession No. AB028863
	C7	GenBank Accession No. AF132963
	C8	Hofbauer, "The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption," <i>J. Bone Miner. Res.</i> , 15(1):2-12, 2000.
↓	C9	Ishida <i>et al.</i> , "Protein that makes sense in the Argentine ant," <i>Naturwiss.</i> , 89:505-507, 2002.
RLi	C10	Kong <i>et al.</i> , "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis," <i>Nature</i> , 397:315-323, 1999.

25336774.1

EXAMINER:

Ruixiang Li

DATE CONSIDERED:

2/24/2005

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSC:761US

Serial N .

10/629,329

Applicant

Bryant G. Darnay

Filing Date:

July 29, 2003

Group:

Unknown 1646

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
RLi	C11	Li <i>et al.</i> , "RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism," <i>Proc. Natl. Acad. Sci., USA</i> , 97(4):1566-1571, 2000.
	C12	Mizuno <i>et al.</i> , "Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin," <i>Biochem. Biophys. Res. Commun.</i> , 247:610-615, 1998.
	C13	Okahashi <i>et al.</i> , "Osteoclast differentiation is associated with transient upregulation of cyclin-dependent kinase inhibitors p21WAF1/CIP1 and p27KIP1," <i>J. Cell Biochem.</i> , 80(3):339-345, 2001.
	C14	Pullen <i>et al.</i> , "CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs)," <i>J. Biol. Chem.</i> , 274:14246-14254, 1999.
↓	C15	Scheven <i>et al.</i> , "In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population," <i>Nature</i> , 321:79-81, 1986.
RLi	C16	Takayanagi <i>et al.</i> , "Induction and activation of the transcription factor NFATc1 (NAFT2) integrate RANKL signaling in terminal differentiation of osteoclast," <i>Dev. Cell</i> , 3(6):889-901, 2002.

25336774.1

EXAMINER:

Renshaw Li

DATE CONSIDERED:

2/21/2015

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)